Effects of selective cyclooxygenase-2 and nonselective cyclooxygenase inhibition on myocardial function and perfusion

Keyphrases

• Myocardial Function 100%
• Cyclooxygenase Inhibitors 100%
• Cyclooxygenase-2 100%
• Myocardial Perfusion 100%
• Cyclooxygenase-2 Inhibitors 100%
• Non-selective 100%
• Serotonin 33%
• Rate Pressure Product 33%
• Myocardial Blood Flow 33%
• Cardiovascular Risk 33%
• High Blood Pressure 33%
• Between-group 33%
• Prostaglandins 33%
• Oxidative Stress 33%
• Vascular Endothelial Growth Factor 33%
• Physiologic 33%
• Tumor Necrosis Factor-α 33%
• Vascular Smooth muscle Cells 33%
• Immunostaining 33%
• 3-group 33%
• Immunoblotting 33%
• Yorkshire Swine 33%
• Prostacyclin 33%
• Celecoxib 33%
• Cardiomyocyte Apoptosis 33%
• Thromboxane 33%
• Thromboxane A2 Receptor 33%
• Adverse Cardiovascular Events 33%
• Drug Control 33%
• Naproxen 33%
• Oxidized Proteins 33%
• Microvascular Reactivity 33%
• COX Inhibition 33%
• Phosphorylated Endothelial Nitric Oxide Synthase 33%
• Nonselective Nonsteroidal Anti-inflammatory Drugs 33%
• Vascular Physiology 33%
• Thromboxane A2 Synthase 33%
• COX Inhibitors 33%

Medicine and Dentistry

• Heart Function 100%
• Cyclooxygenase 2 100%
• Prostaglandin Synthase 100%
• Heart Muscle Perfusion 100%
• Cyclooxygenase 2 Inhibitor 100%
• Oxidative Stress 66%
• Cardiovascular System 33%
• Heart Muscle Blood Flow 33%
• Hypertension 33%
• Endothelial Nitric Oxide Synthase 33%
• Immunohistochemistry 33%
• Immunoblotting 33%
• Programmed Cell Death 33%
• Tumor Necrosis Factor 33%
• Vasculotropin 33%
• Cardiovascular Risk 33%
• Prostaglandin 33%
• Prostacyclin 33%
• Serotonin 33%
• Celecoxib 33%
• Nonsteroid Antiinflammatory Agent 33%
• Synthetase 33%
• Vascular Smooth Muscle 33%
• Thromboxane 33%
• Naproxen 33%
• Thromboxane A2 Receptor 33%
• Vascular Physiology 33%